Daily non-political popular news in brief.

Support groups don't extend survival of metastatic breast cancer patients, Stanford study finds

07-23-2007 · EurekAlert!

A new study from a team of Stanford University School of Medicine researchers led by David Spiegel, MD, shows that participating in support groups doesn't extend the lives of women with metastatic breast cancer. The results differ from oft-cited previous findings by Spiegel, that showed group psychotherapy extended survival time.

Keywords: support, groups, extend, survival, metastatic, breast, cancer, patients, stanford, study, group, patient

« Previous | Next »

Similar news on "Support groups don't extend survival of metastatic breast cancer patients, Stanford study finds":

Group therapy fails to improve breast cancer survival
07-23-2007 · EurekAlert!
A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.
Similar news · Read more »
New research disproves belief that group psychotherapy extends the lives of cancer patients
05-01-2007 · EurekAlert!
Previously-published research has given credence to the notion that psychotherapy extends the lives of people with cancer. In fact, one in four cancer patients believe that science supports the idea that participating in group therapy will extend their lives. However, researchers as the University of Pennsylvania School of Medicine concluded -- after an extensive research review -- that there is no compelling evidence linking psychotherapy or support groups with survival among cancer patients.
Similar news · Read more »
Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »
Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
Study: Praying online helps cancer patients
01-03-2007 · EurekAlert!
Breast cancer patients who pray in online support groups can obtain mental health benefits, according to a new study conducted by the University of Wisconsin-Madison Center of Excellence in Cancer Communications Research that was funded by the National Cancer Institute.
Similar news · Read more »
Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
Breast cancer gene mutation more common in Hispanic, young black women, Stanford/NCCC study finds
12-25-2007 · EurekAlert!
A genetic mutation already known to be more common in Ashkenazi Jewish breast cancer patients is also prevalent in Hispanic and young African-American women with breast cancer, according to one of the largest, multiracial studies of the mutation to date.
Similar news · Read more »
Cancer drug can extend survival in patients with deadly brain tumors
02-20-2007 · EurekAlert!
Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.
Similar news · Read more »
Research shows survival benefit for leukemia patients treated with arsenic trioxide
06-04-2007 · EurekAlert!
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Similar news · Read more »
Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »